Metabolism Disorder TRIZ Cases

Codon optimization of hOTC sequences in viral vectors resolves mRNA instability and insufficient expression levels.

Amino acid substitutions enhance peptide stability, eliminating reconstitution time and aggregation risks in hypoglycemia treatment.

STRO-1 cell therapy reduces triglycerides and improves glucose tolerance without side effects.

Lactobacillus plantarum PL-02 mediates calcium absorption via TRPV6 upregulation, avoiding kidney stone risks from high-dose supplements.

Insulin-conjugates bind endogenous proteins to release drug payloads in response to saccharide levels.

Interleukin-1 receptor antagonist protein promotes epithelial cell proliferation to protect intestinal mucosa tissue.

ActRII inhibitor polypeptides increase bone mineral density and reduce vascular calcium levels to address mineral imbalances in chronic kidney disease.

Oral pharmaceutical compositions combine GLP-1 analogues with protease inhibitors and chelators to overcome gastric degradation barriers.

Injecting substance P into the celiac artery restores beta cell mass and insulin production in recent-onset type 1 diabetes.

A transdermal insulin formulation replaces mechanical injections with chemical permeation, reducing caretaker burden and hypoglycemia risk.

Balanced dual agonist peptides reduce gastrointestinal side effects while controlling blood glucose.

Anti-PCSK9 monoclonal antibody blocks PCSK9-LDLR association, upregulating LDLR expression to resolve statin inefficacy in hypercholesterolemia patients.

Specific biomarkers including CD5 antigen-like and adiponectin enable accurate identification of pre-diabetes risk.

A staged protocol uses EGF, nicotinamide, and Noggin to drive endodermal cells into NKX6-1 positive pancreatic progenitors.

Antigen binding proteins bind the beta-Klotho-FGFR complex to trigger FGF21-like signaling, lowering blood glucose and serum lipid levels.

Adjusting the linoleic to alpha-linolenic acid ratio in infant formulas controls visceral adipogenesis, lowering later obesity risk.

Esterifying fenofibric acid with isopropyl bromide in dimethyl sulfoxide and alkyl acetate solvents eliminates corrosive acid requirements.

Fruit and vegetable pomace alters carbohydrate uptake in the gastrointestinal system through dietary fiber adsorption.

Supercritical fluid extraction isolates schisandrin for solid formulations, resolving poor dosing accuracy and storage instability in alcoholic tinctures.

Vasoactive intestinal peptide fragments reduce established fibrosis while lowering molecular complexity compared to full-length molecules.

Live Gemella sanguinis bacteria reduce fasting blood glucose levels and improve glucose tolerance in subjects with metabolic disorders.

Momordica charantia extract regulates circadian rhythms by enhancing CLOCK, ARNTL, and PER2 gene expressions without addiction risks.

Low glucose concentration combined with Wnt ligand drives definitive endoderm formation, resolving the trade-off between efficiency and beta cell resemblance.

Selected Bifidobacterium strains adsorb cholesterol onto cell walls and hydrolyze bile salts to lower LDL levels.

Antibodies bind human and mouse MET receptors with high affinity, resolving low cross-reactivity that limits pre-clinical model utility.

Telmisartan blocks angiotensin II receptor 1, resolving angiotensin escape from ACE inhibitors and improving renal function in cats.

DPP-4 inhibitors block GLP-1 degradation to sustain glycemic control without hypoglycemia risk or secondary drug failure.

A composite herbal formulation reduces body weight and visceral fat without severe side effects.

A Lactobacillus plantarum strain with elevated bile salt hydrolase activity paired with oligosaccharides to modify cholesterol absorption.

Cationic polymers with substituted phenyl boronic acid groups condense mucin to form a physical barrier in the gastrointestinal tract.

SDC2+ exosome compositions reduce inflammation and insulin requirements by extracting therapeutic activity from mesenchymal stem cells.

A tagatose coffee mix lowers blood glucose levels by replacing high glycemic sweeteners with a low glycemic alternative.

Linoleic and oleic acids inhibit digestive lipase activity, reducing blood triglyceride levels without synthetic drug side effects.

Bacillus strains lower lipid peroxide levels to improve meat quality and eliminate antibiotic resistance.

Targeted melanocortin receptor ligands improve glucose regulation and insulin metabolism without requiring weight loss.

Controlling monovalent metal ions below 25 mg/g protein prevents precipitation and sedimentation while maintaining high protein content.

High-moisture aprotic polar solvents combined with ionization stabilizing excipients resolve device material incompatibility and preserve chemical stability.

Bletilla formosana extract stimulates cell migration to resolve impaired diabetic wound closure without hepatotoxicity.

Plastid integration of therapeutic genes overcomes nuclear gene silencing to enable stable oral delivery of high-yield pharmaceutical proteins.

Fc-arginine gene carrier condenses anionic DNA via electrostatic interaction for stable oral delivery.

Sortase enzyme cleaves single-chain insulin precursors at the LPXT motif to produce derivatives.

A chemically crosslinked alginic acid gel encloses pancreatic islets to provide immune isolation and sustained glucose regulation.

XPRO1595 inhibits soluble TNF-α to reduce lipocalin-2 and reverse hepatic steatosis caused by high-fat diets.

Optimized hamster Reg3 gamma peptide transforms pancreatic ductal cells into new islets, addressing insufficient beta cell regeneration in diabetes therapy.

Cyclic polypeptide compounds bind human proprotein convertase subtilisin/kexin type 9 to block receptor interaction, lowering LDL cholesterol levels.

Resistant starch mediates curcuminoid delivery to overcome fast metabolism and poor absorption.

Replacing natural montmorillonite with synthetic zeolite reduces required dose from 1500 ppm to under 500 ppm while maintaining zootechnical performance.

A cell-permeable truncated SOCS3 recombinant protein disrupts leptin receptor interactions to restore metabolic control.

Screening test compounds against mitochondrial electron transport complex IV subunits identifies therapeutic agents.